The Application of Machine Learning in the Corona Era, With an Emphasis on Economic Concepts and Sustainable Development Goals
Table 4.
Important Vaccines under development
| Vaccines | Trial phase (1 2 3) | Prior vaccine development experience | Approval status | Pre-orders (Later, -, Soon) | Immune response | | Astrazeneca-Oxford | 1 2 3 | No | Review | Soon | 70%* | | Cansino biologics | 1 2 3 | Yes | Limited | Soon | High | | Gamaleya research institute | 1 2 3 | Yes | Limited | Soon | Moderate | | Inovio-cepi | 1 2 3 | No | - | Later | Not reported | | Johnson & Johnson Barda Janssen | 1 2 3 | Yes | - | Later | Moderate | | Moderna-Niaid | 1 2 3 | No | Review | Soon | 94.5% | | Novavax | 1 2 3 | No | - | - | High | | Pfizer-Biontech | 1 2 3 | No | Review | Soon | 95% | | Sinopharm-Beijing institute of biological products | 1 2 3 | Yes | Limited | - | Moderate | | Sinovac-instituto Butantan | 1 2 3 | No | - | - | Low |
|
|
